All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can CRISPR be used for adoptive T-cell therapy in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Eliana Ruggiero, IRCCS Ospedale San Raffaele, Milan, IT. We asked, How can CRISPR be used for adoptive T-cell therapy in AML?

How can CRISPR be used for adoptive T-cell therapy in AML?

Ruggiero outlines the concept of adoptive T-cell therapy in AML. She discusses how CRISPR/Cas9 technology has demonstrated promising results in this area, in particular by limiting graft-versus-host disease and transplant-related toxicities.

 

Share:
More about...